Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Acute Myeloid Leukemia
NCT02351037Phase 2Terminated
- Sponsor
- Pharmacyclics
- Start
- Feb 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib in acute myeloid leukemia (AML) (3 arms), sponsored by Pharmacyclics. Primary endpoints: Overall Remission Rate at 12 months and Safety and Tolerability. Started Feb 2015; status: terminated.
02
Drugs
ibrutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02351037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351037.